Q3 2026 Revvity Earnings Conference Call - REVVITY INC

Financial Performance:

• Total Q3 2026 pro forma revenue reached $710 million, delivering 7% organic growth (9% Life Sciences, 5% Diagnostics).
• Pro forma adjusted operating margin expanded to 29.4% (40 bps above guidance), driven by sales leverage and operational efficiency.
• Pro forma adjusted EPS hit $1.37, beating the midpoint of guidance by 8 cents, representing 21% YoY growth.
• Free cash flow generation was robust at $152 million in Q3, achieving 99% conversion of adjusted net income; YTD FCF exceeded $450 million with 105% conversion.
• Balance sheet strengthened with a net debt-to-EBITDA leverage ratio of 2.3x; gross leverage targeted below 3.0x by year-end.
• Repayment of a $500 million euro note reduced gross leverage; outstanding long-term debt is 100% fixed-rate with a weighted average maturity of 7 years and interest rate of 2.8%.
• Q3 excluded the negative impact of the China immunodiagnostics business, which will be divested in 2027.

Guidance and Future Outlook:

• Full-year 2026 pro forma organic growth outlook raised to approximately 5% (previously 4-5%), driven by accelerating demand.
• Full-year 2026 pro forma adjusted EPS guidance raised to a range of $5.40–$5.45, implying ~12% YoY growth.
• Full-year 2026 pro forma revenue projected at approximately $2.86 billion.
• Q4 2026 pro forma organic growth guidance is approximately 5%, with revenue expected at a midpoint of $755 million.
• Q4 2026 pro forma adjusted operating margin guidance is slightly above 32%, reflecting continued mix benefits and efficiency.
• Q4 2026 pro forma adjusted EPS is guided to approximately $1.60 per share.
• Management anticipates AI-related demand to broaden across the portfolio beyond high-content screening in 2027.

Business Segments and Product Lines:

• Life Sciences (9% organic growth): Reagents grew in the high single digits (strongest performance in years), instruments grew in the strong mid-single digits, and Signal Software grew in the upper teens.
• Diagnostics (5% organic growth): Immunodiagnostics grew in the high single digits; Reproductive Health grew in the low single digits.
• New Product Launches: Launched "Signals LabGistics," an AI-native workflow coordination tool; introduced GSP T1D triplex kit in Europe for early Type 1 diabetes detection.
• Instrumentation: High-content screening (HCS) backlog continued to increase; capacity expansion undertaken to meet elevated demand.
• Operational Efficiency: Consolidation of Life Sciences and Diagnostics R&D/manufacturing in Hopkinton, MA, and modernized operations in Europe contributed to margin expansion.
• M&A Impact: Recent ACD Labs acquisition contributed ~1% to revenue growth in Q3 and ~75 bps to full-year growth.

Market and Competitive Landscape:

• Pharma and biotech end-market demand is recovering, moving away from policy-related headwinds experienced in the previous year.
• AI demand is expanding from early high-content screening applications to broader portfolio segments including reagents, high-throughput screening, and detection.
• Geographic performance: Europe and Americas grew double digits; APAC saw low single-digit decline due to reproductive health pressures in China, though Life Sciences in China grew double digits.
• Management sees customers as only beginning to "scratch the surface" regarding AI integration in preclinical workflows.

Risks and Challenges:

• Ongoing divestiture of the China immunodiagnostics business (excludes a 160 bps margin headwind in Q3).
• China's reproductive health market faces headwinds due to declining birth rates, though this segment represents only ~1% of total revenue.
• FX rates acted as an approximate 1% headwind on growth in Q3 and are expected to contribute ~50 bps tailwind for the full year.
• AI demand is in early stages, requiring continued investment to capture long-term value.

Management Commentary and Tone:

• Tone was highly confident and optimistic, highlighting a "broad-based" recovery and the first time the company has demonstrated its "true potential" in several quarters.
• Prahlad Singh (CEO) emphasized that the current recovery is sustainable, citing multi-quarter trends in customer spending and backlog acceleration.
• Max Grzykowiak (CFO) highlighted the structural nature of margin improvements, citing 40%+ incremental margins as a sustainable feature of the business.
• Management plans to detail AI strategies and R&D evolution at the Investor Day on November 13, 2026.

Analyst Questions and Answers:

• Reagents: Q3 high-single-digit growth included a ~100 bps benefit from a bulk screening order; Q4 outlook moderates to mid-single digits as this timing item does not recur, yet underlying demand remains strong.
• AI Exposure: AI is impacting reagents and instruments from high-content to high-throughput and imaging; no portfolio segments identified as negatively impacted.
• Instrument Backlog: HCS backlog increased despite strong comps; no "backlog flush" occurred, as demand remained consistent across the instrument portfolio.
• Diagnostics Q4: Expects similar mid-single-digit organic growth for the segment, with immunodiagnostics at high-single digits and reproductive health at low-single digits.
• Genomics England: Currently contributing ~$25 million annually; negotiations ongoing to expand the partnership.
• Software Funnel: Signals business shows strong customer feedback on new AI products; 2026 will not see massive contribution from new launches, but pipeline is robust.
• Margin Sustainability: Management confirmed 40%+ incremental adjusted operating margins are sustainable and structural.

Other Key Points:

• Q3 represented the strongest performance in the Life Sciences reagent business in several years across pharma, biotech, and academia/government.
• Management highlighted that AI demand is driving the need for exponentially more biological data generation from wet labs.
• The company expects to exit the year with net leverage approaching 2.0x after the Euro note repayment.
• New T1D diagnostic test leverages existing GSP platform infrastructure to expand into early childhood screening.